[go: up one dir, main page]

PE20150904A1 - Profarmacos de rebamipida novedosos, metodo de preparacion y uso de los mismos - Google Patents

Profarmacos de rebamipida novedosos, metodo de preparacion y uso de los mismos

Info

Publication number
PE20150904A1
PE20150904A1 PE2014002534A PE2014002534A PE20150904A1 PE 20150904 A1 PE20150904 A1 PE 20150904A1 PE 2014002534 A PE2014002534 A PE 2014002534A PE 2014002534 A PE2014002534 A PE 2014002534A PE 20150904 A1 PE20150904 A1 PE 20150904A1
Authority
PE
Peru
Prior art keywords
rebamipida
novelty
drugs
depth
preparation
Prior art date
Application number
PE2014002534A
Other languages
English (en)
Inventor
Eui-Hwan Cho
Sung Ju Choi
Sung Woo Lee
Hee Jong Shin
Ho Seok Kwon
Jeong Ho Joo
Hyun Tae Kim
Woo-Heon Song
Jong Bae Yoon
Ki Seok Park
Ho Joon Park
Ho Tae Nam
Jae Woong Lee
Original Assignee
Astech Co Ltd
Samjin Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49783488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20150904(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astech Co Ltd, Samjin Pharm Co Ltd filed Critical Astech Co Ltd
Publication of PE20150904A1 publication Critical patent/PE20150904A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)

Abstract

Se proporciona una composicion farmaceutica que comprende el profarmaco de rebamipida novedoso como principio activo. El profarmaco de rebamipida tiene una tasa de absorcion aumentada 25 veces en comparacion con la propia rebamipida, y puede aplicarse a la profilaxis o la terapia de ulcera gastrica, gastritis aguda, gastritis cronica, xeroftalmia, cancer, osteoartritis, artritis reumatoide u obesidad
PE2014002534A 2012-06-26 2013-06-26 Profarmacos de rebamipida novedosos, metodo de preparacion y uso de los mismos PE20150904A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20120068394 2012-06-26

Publications (1)

Publication Number Publication Date
PE20150904A1 true PE20150904A1 (es) 2015-06-13

Family

ID=49783488

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2016000265A PE20160285A1 (es) 2012-06-26 2013-06-26 Profarmacos de rebamipida novedosos, metodo de preparacion y uso de los mismos.
PE2014002534A PE20150904A1 (es) 2012-06-26 2013-06-26 Profarmacos de rebamipida novedosos, metodo de preparacion y uso de los mismos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2016000265A PE20160285A1 (es) 2012-06-26 2013-06-26 Profarmacos de rebamipida novedosos, metodo de preparacion y uso de los mismos.

Country Status (27)

Country Link
US (1) US11420963B2 (es)
EP (1) EP2865669B1 (es)
JP (1) JP6032451B2 (es)
KR (1) KR101452277B1 (es)
CN (1) CN104662004B (es)
AP (1) AP2015008233A0 (es)
AR (1) AR097226A1 (es)
AU (1) AU2013281442B2 (es)
BR (1) BR112014032627A8 (es)
CA (1) CA2877853C (es)
CL (1) CL2014003496A1 (es)
CO (1) CO7240352A2 (es)
ES (1) ES2875863T3 (es)
IL (1) IL236479A0 (es)
MA (1) MA37676B1 (es)
MX (1) MX2015000023A (es)
NZ (1) NZ704023A (es)
PE (2) PE20160285A1 (es)
PH (1) PH12015500172B1 (es)
RU (1) RU2612509C2 (es)
SA (1) SA113340675B1 (es)
SG (1) SG11201408711PA (es)
TW (1) TWI483727B (es)
UA (1) UA113990C2 (es)
UY (1) UY34882A (es)
WO (1) WO2014003424A1 (es)
ZA (1) ZA201500450B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101692578B1 (ko) * 2013-04-18 2017-01-03 삼진제약주식회사 레바미피드 또는 이의 전구체를 포함하는 안구건조증의 예방 또는 치료를 위한 경구용 약제학적 조성물
WO2016108319A1 (ko) * 2015-01-02 2016-07-07 삼진제약 주식회사 신규 레바미피드 전구체의 염 및 이의 용도
KR20170094584A (ko) * 2016-02-11 2017-08-21 삼진제약주식회사 레바미피드 전구체를 포함하는 면역질환 및 대사성질환의 예방 또는 치료를 위한 경구투여용 약제학적 조성물
KR102190019B1 (ko) * 2018-10-23 2020-12-15 삼진제약주식회사 쇼그렌 증후군 예방 또는 치료용 조성물
ES2913792T3 (es) * 2019-09-03 2022-06-06 Square Power Ltd Rebamipida para uso en la profilaxis y el tratamiento de la enfermedad celíaca
EP3797773A1 (en) * 2019-09-03 2021-03-31 Square Power Ltd Rebamipide for use in prophylaxis and treatment of cancer
CN111595985B (zh) * 2020-07-09 2022-03-29 苏州正济药业有限公司 一种用hplc测定瑞巴派特有关物质的分析方法
CN121039146A (zh) 2023-04-27 2025-11-28 伊姆霍特克斯有限公司 作为nod2激动剂的去胞壁酰肽二酸及其用途
WO2024224093A1 (en) 2023-04-27 2024-10-31 Imhotex Limited Desmuramylpeptide dieesters as nod2 agonists and use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI80022C (fi) * 1982-07-05 1990-04-10 Otsuka Pharma Co Ltd Foerfarande foer framstaellning av ett nytt, terapeutiskt anvaendbart karbostyrilderivat.
JPS6019767A (ja) 1983-07-11 1985-01-31 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体を有効成分とする抗潰瘍剤
JP3621463B2 (ja) * 1995-04-26 2005-02-16 大塚製薬株式会社 カルボスチリル誘導体ビスマス塩
KR100669823B1 (ko) 2001-02-20 2007-01-17 경동제약 주식회사 2-(4-클로로벤조일아미노)-3-[2(1ｈ)-퀴놀리논-4-일]프로피온산의 제조방법 및 그 중간체
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
KR20040104020A (ko) 2003-06-02 2004-12-10 진양제약주식회사 신규 레바미피드 리지네이트와 레바미피드 아르기니네이트및 이 신규 레바미피드 리지네이트와 레바미피드아르기니네이트를 유효성분으로 함유하는 약학적 제제
TWI363626B (en) * 2004-11-15 2012-05-11 Otsuka Pharma Co Ltd Aqueous ophthalmic suspension of crystalline rebamipide
WO2006059781A1 (en) * 2004-12-01 2006-06-08 Otsuka Pharmaceutical Co., Ltd. Improved process for preparing rebamipide
JP2008105970A (ja) 2006-10-24 2008-05-08 Ohara Yakuhin Kogyo Kk ジヒドロキノリン誘導体の製造方法及びその中間体
WO2008074853A1 (en) * 2006-12-21 2008-06-26 Novartis Ag Ophthalmic rebamipide solution
KR101032600B1 (ko) 2008-08-11 2011-05-06 동우신테크 주식회사 고순도 레바미피드의 제조방법
KR101182114B1 (ko) * 2010-03-05 2012-09-12 한림제약(주) 유효성분으로서 레바미피드를 함유하는 골관절염 예방 또는 치료용 약학 조성물
CN102174015B (zh) 2011-03-07 2013-10-16 江西同和药业有限责任公司 瑞巴派特的精制方法

Also Published As

Publication number Publication date
MA37676B1 (fr) 2017-07-31
BR112014032627A8 (pt) 2021-08-31
UA113990C2 (xx) 2017-04-10
US11420963B2 (en) 2022-08-23
SG11201408711PA (en) 2015-01-29
AU2013281442B2 (en) 2016-09-15
JP6032451B2 (ja) 2016-11-30
RU2015102043A (ru) 2016-08-10
AU2013281442A1 (en) 2015-02-12
KR101452277B1 (ko) 2014-10-24
AR097226A1 (es) 2016-03-02
SA113340675B1 (ar) 2015-08-16
IL236479A0 (en) 2015-02-26
ZA201500450B (en) 2016-05-25
US20150141409A1 (en) 2015-05-21
WO2014003424A1 (ko) 2014-01-03
PE20160285A1 (es) 2016-04-27
KR20140001767A (ko) 2014-01-07
CL2014003496A1 (es) 2015-08-07
EP2865669A4 (en) 2015-12-02
PH12015500172A1 (en) 2015-03-16
CA2877853A1 (en) 2014-01-03
BR112014032627A2 (pt) 2017-06-27
JP2015522585A (ja) 2015-08-06
EP2865669A1 (en) 2015-04-29
PH12015500172B1 (en) 2015-03-16
EP2865669B1 (en) 2021-04-28
RU2612509C2 (ru) 2017-03-09
AP2015008233A0 (en) 2015-01-31
CO7240352A2 (es) 2015-04-17
ES2875863T3 (es) 2021-11-11
MX2015000023A (es) 2015-10-05
CN104662004A (zh) 2015-05-27
TWI483727B (zh) 2015-05-11
TW201402118A (zh) 2014-01-16
MA37676A1 (fr) 2016-10-31
UY34882A (es) 2014-01-31
CA2877853C (en) 2018-01-02
NZ704023A (en) 2016-03-31
CN104662004B (zh) 2017-04-19

Similar Documents

Publication Publication Date Title
PE20150904A1 (es) Profarmacos de rebamipida novedosos, metodo de preparacion y uso de los mismos
CR20130247A (es) Compuestos tricíclicos de la pi3k y métodos de uso
CL2016000468A1 (es) Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso.
CL2015002164A1 (es) Formulación combinada de dos compuesos antivirales.
MX338515B (es) Derivados de tetrahidroquinolina utiles como inhibidores de bromodominio.
BR112015019432A2 (pt) Compostos de tubulisina, métodos de produção e uso
MY196173A (en) Cot Modulators And Methods Of Use Thereof
WO2014108571A3 (en) Cancer drug and uses
ZA201601534B (en) Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
UA109010C2 (en) Morpholino pyrividines and their use in therapy
EA201290833A1 (ru) Применение амисульприда в качестве противорвотного средства
MX376008B (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
DOP2014000255A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
EA201491523A1 (ru) Саморазрушающиеся цементные композиции и связанные с ними применения в борьбе с поглощением
AR103077A1 (es) Método para la producción de un sistema de administración farmacéutica
ECSP12012354A (es) Compuestos heterocíclicos, su preparación y su aplicación terapéutica
BR112015015116A2 (pt) extrato de fruta solúvel em água, composição, e, forma de dosagem
AR089320A1 (es) Cepa de lactobacillus mucosae
CL2011002782A1 (es) Combinacion farmaceutica antitumoral que comprende ave8062 y sorafenib, en forma de base o sal de acido util para tratar tumores solidos, como un sarcoma, cancer de pulmon, ovarios, riñon o higado.
EA201591450A1 (ru) Фармацевтический состав, содержащий гликозаминогликан
EA201600394A1 (ru) Трициклические соединения пиперидина
EA201590656A1 (ru) Азаиндолины
TR201100150A2 (tr) Suda çözünür dozaj formları
CL2016000397A1 (es) Tratamiento contra el cáncer
CL2012003250A1 (es) Uso de un galactolipido en combinacion con acido ascorbico y/o un derivado del mismo que sirve para proteger una composicion contra la oxidacion; metodo para la preparacion de la composicion, composicion; y producto.

Legal Events

Date Code Title Description
FD Application declared void or lapsed